Serum S100A8/S100A9 is associated with increased risk of brain metastasis in patients with inflammatory breast cancer.
Saved in:
| Title: | Serum S100A8/S100A9 is associated with increased risk of brain metastasis in patients with inflammatory breast cancer. |
|---|---|
| Authors: | Villodre ES; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston TX.; Department of Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston TX., Song J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston TX., Hu X; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston TX.; Department of Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston TX., Gomez K; Department of Biological Sciences, The University of Texas at Brownsville, TX, USA., Cohen EN; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston TX., Reuben JM; Department of Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston TX., Nasrazadani A; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston TX., Lim B; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston TX., Tripathy D; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston TX.; Department of Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston TX., Woodward WA; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston TX.; Department of Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston TX., Krishnamurthy S; Department of Pathology, and The University of Texas MD Anderson Cancer Center, Houston TX.; Department of Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston TX., Debeb BG; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston TX.; Department of Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston TX. |
| Corporate Authors: | MDACC Inflammatory Breast Cancer Team |
| Source: | MedRxiv : the preprint server for health sciences [medRxiv] 2026 Jan 22. Date of Electronic Publication: 2026 Jan 22. |
| Publication Type: | Journal Article; Preprint |
| Journal Info: | Country of Publication: United States NLM ID: 101767986 Publication Model: Electronic Cited Medium: Internet NLM ISO Abbreviation: medRxiv Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
